The World Health Organization (WHO) has expressed serious concern about monkeypox and declared it a global emergency. The new strain of this virus, Clade-1, is considered more contagious and has a higher death rate. To combat this, India has developed its own RT-PCR test kit for monkeypox, which has been approved by the Central Drugs Standard Control Organization (CDSCO).
India’s New RT-PCR Test Kit
Siemens Healthineers has received approval from CDSCO for the IMDX Monkeypox Detection RT-PCR kit. This achievement is significant for India’s “Make in India” initiative and represents a crucial step in fighting the monkeypox public health emergency.
The IMDX Monkeypox Detection RT-PCR kit will be manufactured at Siemens’ molecular diagnostics unit in Vadodara, which has the capacity to produce 1 million reactions per year. The factory is fully prepared to supply the kits.
Detects Both Clade I and Clade II Strains
The IMDX Monkeypox Detection RT-PCR kit is a sophisticated molecular diagnostic test that checks two different regions of the viral genome. This allows it to detect both Clade I and Clade II strains of the virus, ensuring thorough identification across various viral strains.
This PCR kit is designed to fit seamlessly into existing lab workflows, eliminating the need for additional machines. It will make use of current COVID testing infrastructure, enhancing efficiency.
Results in 40 Minutes
According to Siemens Healthcare Private Limited, results from this kit will be available within 40 minutes. In contrast, results from older kits typically take 1-2 hours. The IMDX Monkeypox RT-PCR test kit, validated by the ICMR-National Institute of Virology in Pune, claims 100% sensitivity and specificity. It adheres to Indian regulatory guidelines and meets the highest global standards.
